INS and type 2 diabetes mellitus: Emerging clinical studies showed that IL-1 receptor antagonist (anakinra) and IL-1β-specific antibody (gevokizumab, canakinumab, LY2189102) treatment improved glucose metabolism and insulin secretion in patients with T2D (61, 83).